CONMED Corporation account plan
surgical, patient monitoring products
At a glance
CONMED is a Largo, Florida medical technology company making surgical devices, with FY2025 net sales of $1,374.7 million and about 3,900 employees.
CONMED Corporation is a medical technology company headquartered in Largo, Florida that provides devices and equipment for surgical procedures in orthopedics, general surgery, gynecology and thoracic surgery. It sells directly to more than 6,000 US hospitals, surgery centers and other institutions and in over 100 countries through subsidiaries and distributors; about 86% of FY2025 revenues came from single-use products. FY2025 net sales were $1,374.7 million, up 5.2%, and net income was $47.1 million vs $132.4 million. It had about 3,900 full-time employees at December 31, 2025 and manufactures substantially all products in the United States and Mexico. Pat Beyer is President and Chief Executive Officer.
Business units
General surgery
58% of FY2025 net sales ($800.1 million)AirSeal insufflation for minimally invasive and robotic surgery, Buffalo Filter smoke evacuation, energy generators, endomechanical instruments and patient monitoring. Gastroenterology products were exited in 2026, so Q3 2026 sales fell 6.5% to $186.7 million, while AirSeal, endomechanical instruments, patient monitoring and smoke evacuation grew.
Orthopedic surgery
42% of FY2025 net sales ($574.6 million)Sports medicine (BioBrace, Y-Knot and Argo anchors, resection, fluid management and visualization), foot and ankle extremities and Hall powered instruments. Q3 2026 sales grew 7.7% to $148.8 million, with international up 12.7% and the US down 1.7% during distributor changes.
Strategic priorities
- Three growth platforms
- CONMED focuses on three markets (minimally invasive surgery, smoke evacuation, orthopedic soft tissue repair) through AirSeal, Buffalo Filter and BioBrace; the midterm outlook given in January 2026 is 4%-9% growth, general surgery 5%-11% and orthopedics 4%-8%.
- Raise AirSeal penetration
- AirSeal is used in 6%-7% of about 3 million US laparoscopic procedures, with an aim of double-digit share; it gained a US indication for Intuitive's 8 mm hex cannulas on da Vinci 5, and the sales push is to standardize insufflation across every procedure a hospital does, including ambulatory surgery centers.
- Smoke evacuation legislation
- Smoke evacuation laws now cover 23 states and about 60% of the US population, with more than 10 states considering bills; CONMED puts the market at $300-400 million today going to $1 billion.
- Portfolio focus
- The 2025 portfolio review led to the exit from gastroenterology, announced December 5, 2025 and completed in 2026, because "we were probably in too many spaces"; the next step is a multi-year plan including M&A.
- Fix US orthopedics
- Changes to the US commercial organization and distributors are to be finished in the first half of 2027, when Beyer expects US growth again.
- Supply chain transformation
- A consulting firm was engaged in 2025 to improve manufacturing operations in response to tariffs, inflation and supply chain challenges; the supply chain programme is described as focused on resiliency, predictability, scalability and efficiency.
Latest results
In Q3 2026 net sales were $335.6 million, down 0.7% as reported but up 6.7% organic constant currency excluding the exited GI products. Orthopedic surgery grew 7.7% to $148.8 million and general surgery fell 6.5% to $186.7 million. Gross margin rose 720 basis points to 56.4% and net income was $19.8 million vs $2.9 million; adjusted EPS was $1.04. Nine-month net sales were $996.1 million, down 0.5%. FY2026 guidance is organic constant currency growth of 5%-5.5% (previously 5%-6%), adjusted EPS of $4.54-$4.61, adjusted gross margin about 57.5% and free cash flow about $115 million.
Investments and deals
- Gastroenterology exit
- The Gore VIABIL distribution agreement ended January 1, 2026; GI assets were sold in Q1 and Q2 2026 with a 12-month manufacturing and supply agreement for the buyer, for $22.3 million of cash proceeds.
- Debt refinancing
- A $450 million Term A-2 Loan and revolver draw funded the June 15, 2026 repurchase of $645.2 million of the 2.250% Convertible Notes for $637.2 million; total debt was $815.9 million at September 30, 2026.
- Share buybacks replace the dividend
- Dividends were suspended in favour of a $150.0 million repurchase program; 1.2 million shares were bought for $49.9 million through September 30, 2026, and about $62 million of buybacks are expected in 2026.
- BioBrace clinical and regulatory programme
- A 268-patient randomized trial is to finish enrollment in 2026 and publish in 2027; BioBrace was cleared in Brazil in Q3 2026 and Western Europe approvals are expected in 2028.
- M&A capacity
- With leverage at 2.7x, the CFO says there is some M&A capacity, valuation contingent, in general surgery and orthopedics; capital allocation specifics are promised on the Q4 call.
Challenges and risks
- Tariffs and input costs
- Tariffs, inflation and supply chain costs are expected to keep weighing on results; the tariff impact is about $0.35 per share in 2026, and 2027 faces gross margin headwinds from raw material, freight and transport prices.
- Sterilization dependence
- About 31% of products by 2025 revenue are sterilized by third parties using EtO.
- Competition and pricing pressure
- CONMED competes with Medtronic, Johnson & Johnson, Stryker, Smith & Nephew, Arthrex and others; in smoke evacuation the competition is mainly Stryker, and the OEM smoke evacuation business is unpredictable and shrinking.
- Regulatory compliance
- EU MDR raises clinical evaluation, quality and post-market surveillance requirements, with old-directive certificates valid until December 2028; Q3 2026 R&D included $1.9 million of EU MDR compliance costs.
- Higher interest costs
- After the refinancing, the Q3 2026 weighted average interest rate was 4.86% vs 2.80%, and adjusted interest expense rose to $10.5 million from $6.3 million.
What leadership says
“We want to standardize our insufflation portfolio across every procedure the hospital does.”
“for a company our size, we were probably in too many spaces.”
“We believe we'll exit this year in a position where in first half next year, we're driving growth in the United States”
“we do have an appetite for looking at revenue growth accretive M&A opportunities.”
Where a supplier can help
- Clinical marketing and evidence
- Tied to the AirSeal penetration priority: Beyer says CONMED must do a better job telling its story through podium, publication and social media, so medical communications and evidence-generation partners have an opening.
- Sales enablement for standardization and ASCs
- Tied to the AirSeal standardization push and ambulatory surgery centers: territory analytics, account targeting and training tools for reps selling hospital-wide and into ASCs.
- Distributor and commercial restructuring
- Tied to the US orthopedics fix: support for selecting, onboarding and managing distributors and sales agent groups through the first half of 2027.
- Supply chain and manufacturing efficiency
- Tied to the tariff and input cost challenge and the supply chain transformation: sourcing, logistics, sterilization alternatives to EtO and plant efficiency suppliers.
- Regulatory and quality services
- Tied to the EU MDR challenge and BioBrace approvals in new markets: regulatory affairs, clinical evaluation and post-market surveillance services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like CONMED Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- CONMED Corporation Annual Report on Form 10-K for the fiscal year ended December 31, 2025
- CONMED is a Largo, Florida-based medical technology company selling devices and equipment for surgical procedures (orthopedics, general surgery, gynecology, thoracic surgery, gastroenterology); about 3,900 full-time employees and products sold in over 100 countries.
- FY2025 net sales were $1,374.7 million, up 5.2% as reported (5.1% constant currency) from $1,307.0 million; net income fell to $47.1 million from $132.4 million.
- Two product lines in a single operating segment: General surgery 58% of net sales ($800.1 million, +4.9%) and Orthopedic surgery 42% ($574.6 million, +5.6%).
- Recurring model: approximately 86% of revenues come from single-use products; capital products were $190.9 million (-2.1%); international sales approximated 44%.
- Growth drivers named in the report: AirSeal, specimen bags and biliary products in general surgery; sports medicine and BioBrace in orthopedics.
- 2025 was a portfolio-review and cost year: gross margin fell to 54.6% from 56.1%, with $22.2 million of write-offs from cancelled product lines and $12.5 million of manufacturing consulting costs; the company announced on December 5, 2025 its intent to exit its gastroenterology product lines and ended the Gore VIABIL distribution agreement effective January 1, 2026.
- Balance sheet: $800.0 million of 2.250% Convertible Notes due June 15, 2027, which the company expected to refinance; $40.0 million of term loan; $648.5 million available on the revolver; dividends suspended in favour of a $150.0 million buyback program, with at least $25.0 million of repurchases expected annually from 2026.
- Key risks: tariffs and inflation on manufacturing costs, EtO sterilization availability (about 31% of products by revenue sterilized with EtO), competition from Medtronic, Johnson & Johnson, Stryker, Smith & Nephew, Arthrex and others, EU MDR costs, and leverage.
- CONMED Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 net sales $335.6 million, down 0.7% as reported (-0.8% constant currency); nine-month net sales $996.1 million, down 0.5%, after the exit from gastroenterology (Q3 GI sales $1.7 million versus $26.0 million a year earlier).
- Orthopedic surgery grew 7.7% to $148.8 million in Q3 (sports medicine, visualization, BioBrace); General surgery fell 6.5% to $186.7 million, the GI exit partly offset by growth in AirSeal, endomechanical instruments, patient monitoring and smoke evacuation.
- Orthopedic surgery was 44% and General surgery 56% of Q3 sales; international sales approximated 48% of nine-month sales versus 43%.
- Q3 gross margin rose 720 basis points to 56.4%; net income was $19.8 million versus $2.9 million.
- GI exit completed in 2026: assets sold in Q1, further assets sold as a business in Q2, with a 12-month manufacturing and supply agreement for the buyer; $22.3 million of cash proceeds.
- Refinancing: a $450.0 million Term A-2 Loan and revolver draw funded the June 15, 2026 repurchase of $645.2 million of the 2.250% Notes for $637.2 million; total debt $815.9 million at September 30, 2026; Q3 weighted average interest rate 4.86% versus 2.80%.
- $8.5 million of IEEPA tariff refunds booked to cost of goods sold after the Supreme Court ruling; R&D up on EU MDR compliance costs.
- Repurchased 1.2 million shares for $49.9 million through September 30, 2026; about $62 million of buybacks expected in 2026; dividend remains suspended.
- CONMED Q3 2026 earnings call (October 28, 2026)
- Q3 2026 net revenue $335.6 million; organic constant currency growth 6.7% excluding the exited GI products; adjusted EPS $1.04, above the high end of expectations.
- General surgery +6.4% organic constant currency (15.5% international, 1.9% US); AirSeal was the largest driver, with direct Buffalo Filter strong and OEM smoke evacuation sales down.
- Orthopedic surgery +7.2% (12.7% international, -1.7% US) as CONMED restructures its US commercial organization and distributors; Beyer expects US growth again in the first half of 2027.
- AirSeal gained a US indication for Intuitive's 8 mm hex cannulas on da Vinci 5; AirSeal is used in only 6%-7% of more than 3 million US laparoscopic procedures.
- Smoke evacuation laws now in 23 states covering about 60% of the US population (Michigan and Pennsylvania added), with more than 10 states considering bills.
- FY2026 guidance: organic constant currency growth 5%-5.5% (from 5%-6%), adjusted EPS $4.54-$4.61, free cash flow about $115 million, adjusted gross margin about 57.5%, buybacks about $62 million.
- New CFO John Gallagher: leverage 2.7x, appetite for "revenue growth accretive M&A", capital allocation specifics promised on the Q4 call; Beyer declined to comment on takeover rumours.
- CONMED at the Jefferies Global Healthcare Conference (November 16, 2026)
- Beyer sees stable end markets in CONMED's orthopedic and general surgery segments, and expects the same next year.
- AirSeal: general surgery grew 6.4% in Q3; 6%-7% penetration of about 3 million US laparoscopic procedures with an aim of double-digit share; robotic share has been 30%-40%; attachment 35%-40% on Xi and 15%-20% on da Vinci 5.
- Sales push: standardize AirSeal across all of a hospital's procedures; ambulatory surgery centers are growing; new insufflation technology for single-digit low-pressure laparoscopy coming in the next years.
- Buffalo Filter: smoke evacuation market put at $300-400 million today going to $1 billion, growing low double digits; competition mainly Stryker; OEM customers cut from 20+ to a handful.
- BioBrace: US orthopedic distributor changes to be finished in the first half of 2027; Korea approved last October; Western Europe approvals expected in 2028.
- CFO John Gallagher: mid-single-digit sales growth and about 10% EPS growth is the positioning, but 2027 faces gross margin headwinds from raw materials and freight; leverage 2.7x gives some M&A capacity, valuation dependent, in general surgery and ortho.
- CONMED at the 44th Annual J.P. Morgan Healthcare Conference (January 12, 2026)
- Beyer's second J.P. Morgan presentation as CEO: portfolio 58% general surgery / 42% orthopedics, 57% US / 43% international, 86% single-use.
- Midterm outlook: 4%-9% growth; general surgery 5%-11%, orthopedics 4%-8%; AirSeal and direct smoke evacuation high single-digit to double-digit; sports medicine mid to high single digits.
- Three growth platforms: AirSeal, Buffalo Filter and BioBrace (Foot & Ankle rolled into the BioBrace platform); GI exit announced in December 2025 because "we were probably in too many spaces".
- Preliminary 2026 guidance: revenue $1.345-$1.375 billion and adjusted EPS $4.25-$4.45, after a $78-$82 million GI revenue reduction and $0.30-$0.35 incremental tariff impact.
- AirSeal used in over eight million procedures, over 4,000 facilities and over 80 countries; attachment 10%-20% on da Vinci 5 versus about 35% on Xi; about 60% of sales robotic, 40% laparoscopy.
- Smoke evacuation market $300-$350 million going to $1 billion; 20 US states covering over 51% of the population.
- BioBrace: 268-patient RCT to finish enrollment in 2026 and publish in 2027; BioBrace RC delivery device launched in 2025.
- Leverage brought below 3x one quarter early; dividend replaced by buybacks; CFO Todd Garner kept the M&A filters (revenue growth accretive, durable, margin accretive, fair value).
Questions about CONMED Corporation
What does CONMED do?
CONMED makes devices and equipment for surgical procedures, such as AirSeal insufflation, Buffalo Filter smoke evacuation and BioBrace and other sports medicine products, sold to hospitals and surgery centers in over 100 countries.
What is CONMED's revenue?
FY2025 net sales were $1,374.7 million, up 5.2%, with general surgery 58% and orthopedic surgery 42%. Q3 2026 net sales were $335.6 million.
How many employees does CONMED have?
CONMED had about 3,900 full-time employees at December 31, 2025, including approximately 2,400 in operations.
Who leads CONMED?
Pat Beyer is President and Chief Executive Officer; John Gallagher became Chief Financial Officer effective July 15, 2026.
What is CONMED's strategy?
CONMED is focusing on three growth platforms (AirSeal, Buffalo Filter and BioBrace) after exiting gastroenterology, replacing its dividend with buybacks and keeping capacity for revenue growth accretive M&A.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)